RESUMEN
Therapeutic management of blood hypereosinophilia depends on its underlying cause. The cause may be clearly established (parasitic infestation) or more hypothetical (systemic disease). Blood eosinophils often return to normal levels after treatment of either the cause or the associated eosinophilic disease. A targeted approach is more difficult when the cause is unknown (unexplained chronic hypereosinophilia). Various conventional treatments (corticosteroids, hydroxyurea, interferon) have been somewhat effective. The identification of new cellular and molecular markers with diagnostic and pathophysiologic significance makes more rational approaches possible.
Asunto(s)
Eosinofilia/tratamiento farmacológico , Alemtuzumab , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados , Anticuerpos Antineoplásicos/administración & dosificación , Anticuerpos Antineoplásicos/uso terapéutico , Benzamidas , Enfermedad Crónica , Ciclosporinas/administración & dosificación , Ciclosporinas/uso terapéutico , Resistencia a Medicamentos , Eosinofilia/diagnóstico , Eosinofilia/etiología , Eosinofilia/parasitología , Glucocorticoides/uso terapéutico , Humanos , Hidroxiurea/administración & dosificación , Hidroxiurea/uso terapéutico , Mesilato de Imatinib , Factores Inmunológicos/administración & dosificación , Factores Inmunológicos/uso terapéutico , Inmunosupresores/administración & dosificación , Inmunosupresores/uso terapéutico , Interferón-alfa/administración & dosificación , Interferón-alfa/uso terapéutico , Trastornos Mieloproliferativos/complicaciones , Enfermedades Parasitarias/complicaciones , Piperazinas/administración & dosificación , Piperazinas/uso terapéutico , Inhibidores de Proteínas Quinasas/administración & dosificación , Inhibidores de Proteínas Quinasas/uso terapéutico , Pirimidinas/administración & dosificación , Pirimidinas/uso terapéutico , Recurrencia , Factores de TiempoAsunto(s)
Eosinofilia/diagnóstico , Corticoesteroides/uso terapéutico , Anciano , Diagnóstico Diferencial , Eosinofilia/tratamiento farmacológico , Femenino , Humanos , Pulmón/diagnóstico por imagen , Enfermedades Pulmonares Intersticiales/tratamiento farmacológico , Enfermedades Pulmonares Intersticiales/etiología , RadiografíaRESUMEN
The lupus anticoagulant-hypoprothrombinemia syndrome (LAHS)--the association of acquired factor II deficiency and lupus anticoagulant--is a rare disease drastically different from antiphospholipid syndrome in that it may cause predisposition not only to thrombosis but also to severe bleeding. We performed a retrospective study of 8 patients with LAHS referred to 6 French tertiary care centers between January 2003 and February 2011, and a literature review retrieving all related articles published between 1960 and April 2011. Including our 8 new cases, LAHS has been reported in 74 cases. The disease mostly occurs in young adults, with a female to male sex ratio of 1.4. Associated conditions mostly include autoimmune diseases such as systemic lupus erythematosus and infectious diseases. Bleeding is a frequent feature (89% of cases), while arterial and/or venous thrombosis is less common (13%). Factor II level is severely decreased at diagnosis (median value, 11%; range, 1%-40%). LAHS associated with autoimmune diseases is more persistent than LAHS associated with infection, and hemorrhagic complications are more common. Corticosteroids should be considered the first-line treatment, but the thrombotic risk strongly increases during treatment because of the improvement of factor II level. Despite the fact that 50% of patients develop severe bleeding, the mortality rate is <5%, after a median follow-up of 13 months (range, 0.5-252 mo). LAHS associated with autoimmune diseases should be diagnosed and managed carefully because the disease is persistent and severe hemorrhagic complications are common.
Asunto(s)
Síndrome Antifosfolípido/complicaciones , Hipoprotrombinemias/complicaciones , Inhibidor de Coagulación del Lupus , Lupus Eritematoso Sistémico/complicaciones , Protrombina/inmunología , Adolescente , Corticoesteroides , Adulto , Anciano , Síndrome Antifosfolípido/diagnóstico , Enfermedades Autoinmunes/complicaciones , Femenino , Francia , Humanos , Hipoprotrombinemias/diagnóstico , Hipoprotrombinemias/inmunología , Lupus Eritematoso Sistémico/diagnóstico , Masculino , Persona de Mediana Edad , Estudios RetrospectivosRESUMEN
Chronic graft-versus-host disease (GVHD) sometimes mimics autoimmune diseases. We report the case of a 39-year-old patient who presented atypical polymyositis without elevated creatinine phosphokinase, related to a chronic GVHD following interruption of immunosuppressive treatment. Treatment with cyclosporine and corticosteroids resulted in complete and sustained remission of the polymyositis. The symptoms of chronic GVHD-related polymyositis are indistinguishable from those of idiopathic polymyositis. The context of transplantation and a decrease or interruption of prophylaxis suggest the diagnosis of GVHD-related polymyositis, especially if other manifestations of GVHD are associated. A suitably adapted treatment (association of corticotherapy and cyclosporine) improves polymyositis, and in most cases, a normal clinical state is achieved even if the symptoms were severe.
Asunto(s)
Enfermedad Injerto contra Huésped/complicaciones , Polimiositis/etiología , Corticoesteroides/uso terapéutico , Adulto , Ciclosporina/uso terapéutico , Humanos , Inmunosupresores/uso terapéutico , Masculino , Polimiositis/tratamiento farmacológico , Polimiositis/inmunologíaRESUMEN
Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection of the central nervous system with JC virus. Few cases have been described in lupus patients. We describe biopsy-proven PML in a lupus patient receiving mycophenolate mofetil and corticosteroids. Although the patient received no antiviral treatment, the polymerase chain reaction test for JC virus became negative in cerebrospinal fluid after immunosuppressant discontinuation and the patient survived. We discuss the restoration of immune efficiency after immunosuppressant discontinuation in this case and compare the clinical, radiological and histological features with the inflammatory PML form described in human immunodeficiency virus-infected patients.